Quick Answer
Jade Biosciences, Inc. reported Net Income of -$127.41 million for fiscal year 2025.
Jade Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$127.41M -83.0% |
-$69.63M +7.8% |
-$75.52M -46.6% |
-$51.51M -124.3% |
-$22.96M -138.9% |
-$9.61M |
| Diluted EPS | -$3.19 -30.7% |
-$2.44 +15.0% |
-$2.87 -36.7% |
-$2.10 -12.3% |
-$1.87 | — |
| Total Assets | $349.78M +380.5% |
$72.80M -42.9% |
$127.42M -5.8% |
$135.30M -22.8% |
$175.36M +3619.3% |
$4.71M |
| Cash and Equivalents | $88.44M +27.5% |
$69.39M +195.4% |
$23.49M +4.9% |
$22.40M -58.7% |
$54.20M +1085.2% |
$4.57M |
| Stockholders Equity | $332.52M +33251700.0% |
$1.0K -100.0% |
$109.46M -13.6% |
$126.74M -26.5% |
$172.42M +1392.1% |
-$13.34M -266.3% |
| R&D Expense | $93.12M +75.1% |
$53.19M -17.2% |
$64.22M +66.3% |
$38.62M +157.7% |
$14.99M +88.8% |
$7.94M |
| Operating Income | -$113.54M -52.2% |
-$74.60M +8.4% |
-$81.41M -52.9% |
-$53.24M -131.2% |
-$23.02M -159.0% |
-$8.89M |
| Shares Outstanding | 49.32M +1242.7% |
3.67M -86.8% |
27.76M +12.3% |
24.72M +1.3% |
24.41M +9942.3% |
243,076 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$25.18M | -54.7% | +21.7% |
| Diluted EPS | September 30, 2025 | -$0.48 | +90.7% | +44.2% |
| Total Assets | September 30, 2025 | $202.45M | +122.6% | -9.6% |
| Cash and Equivalents | September 30, 2025 | $50.11M | +61.0% | -77.3% |
| Stockholders Equity | September 30, 2025 | $179.35M | +1163.5% | -11.0% |
| R&D Expense | September 30, 2025 | $22.01M | +62.1% | -2.4% |
| Operating Income | September 30, 2025 | -$27.40M | -83.1% | +1.4% |
| Shares Outstanding | September 30, 2025 | 32.63M | +13.0% | +0.0% |
- Jade Biosciences, Inc. reported Net Income of -$127.41 million for fiscal year 2025.
- Jade Biosciences, Inc. showed a decrease of -83.0% in Net Income compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Diluted EPS of $3.19 per share (loss) for fiscal year 2025.
- Jade Biosciences, Inc. showed a decrease of -30.7% in Diluted EPS compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Total Assets of $349.78 million for fiscal year 2025.
- Jade Biosciences, Inc. showed an increase of +380.5% in Total Assets compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Cash and Equivalents of $88.44 million for fiscal year 2025.
- Jade Biosciences, Inc. showed an increase of +27.5% in Cash and Equivalents compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Stockholders Equity of $332.52 million for fiscal year 2025.
- Jade Biosciences, Inc. showed an increase of +810.5% in Stockholders Equity compared to the prior fiscal year.
- Jade Biosciences, Inc. reported R&D Expense of $93.12 million for fiscal year 2025.
- Jade Biosciences, Inc. showed an increase of +75.1% in R&D Expense compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Operating Income of -$113.54 million for fiscal year 2025.
- Jade Biosciences, Inc. showed a decrease of -52.2% in Operating Income compared to the prior fiscal year.
- Jade Biosciences, Inc. reported Shares Outstanding of 49.32 million shares for fiscal year 2025.
- Jade Biosciences, Inc. showed an increase of +1242.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: